Products Built for Scale
breakthrough products designed for massive scale across B2B & B2C markets.
iBreastExam (B2B)
Award-winning, patent-pending, radiation-free, ultra-portable wireless device, usable by lay health-workers to identify and document small, non-palpable lumps, quickly and easily, at the point-of-care.
FDA cleared. In commercialization.
cervAIcal (B2B)
AI enabled mobile colposcope
for cervical cancer screening. CervAIcal is a high-quality, wireless universal cervical examination assistant that goes where the patients are. Ongoing Pilots.
Selfi (B2C)
World's first, at home
breast health monitoring
device / app / platform
built with iBreastExam technologyCommercial launch expected in 2022
Article
Video
Video
Article
Article
Validations & Publications by Global Experts & Clinical Advisors
Our Clinical Advisory Team consists of globally recognized experts and key opinion leaders in breast cancer control and treatment. 7,500 women have been enrolled in multiple investigator-led clinical validations with publications in leading international, peer-reviewed journals:
In conclusion, this study demonstrated excellent negative predictive value of iBE and agreement between iBE and CBE as triage tests for the detection of clinically relevant breast lesions.
iBreastExam identified 15 women with a correlating BIRAD 4 score, of which 3 were confirmed as early-stage breast cancers (Stage IIA, IA and DCIS), none with palpable abnormality on clinical breast examination.97% of the participants reported the test as acceptable and recommendable to relatives and 98% expressed an interest to have iBreastExam made available at local Public Health Centers.
This validation study demonstrated excellent sensitivity of iBE for the identification of clinically significant lesions in patients presenting for diagnostic imaging.
Identified abnormalities in all 39 patients who presented with breast abnormalities and did not demonstrate any false negatives that would prevent the patients from additional evaluation, which makes it a good prescreening tool.
iBreastExam demonstrated significantly (23%) higher sensitivity and moderately (9%) higher specificity to detect breast lesions as compared to CBE. Lower FP rates compared to CBE reduces the pool of women requiring further diagnostic follow-up. iBreastExam requires minimal training and provides objective breast examination with digital documentationAwards & Recognitions
2021 Thought Leader
ACOG TV, ACOG 2021 (American College of Obstetricians and Gynecologists Annual Meeting)
Innovative Health Technology
World Health Organization, Compendium of innovative health technologies for low-resource settings
$1.7M in Global Grant Awards
Innovation, Global Health & Oncology
Pennsylvania Department of Health, CURE Grant Award ($878,000)
Global Health Innovation Grant, Pfizer Foundation ($200,000)
Grants 4 Impact, Bayer Cares Foundation ($175,000)
StartHealth, Unitus Seed Fund ($80,000)
Digital Health Accelerator, University City Science Center ($50,000)
Helsinn – Lyfebulb Oncology Innovation Award ($25,000)
Aspirin Innovation Award, Bayer Cares Foundation ($20,000)
HITLabs World Cup Award NY
Accenture Healthcare Innovation Challenge Award
Inclusive Innovation Award, Anjani Mashelkar Foundation
Arab Health Innov8 Award, Dubai
Lexus Design Award, India
IBM Smart Camp for HealthTech India
Marcum Innovator of the Year Award
PACT Enterprise Awards LifeSciences Startup Company
Interested to invest? Let's go!
